Recurrence of Clostridium difficile-associated diarrhoea prevented by the administration of a whey concentrate from specifically immunised cows; prospective study;Recidieven van Clostridium difficile-geassocieerde diarree voorkómen door toediening van een weiconcentraat van specifiek geïmmuniseerde koeien; prospectief onderzoek

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 35, 2008, Pages 1919-1926

  Bauer, M P ^a   Numan Ruberg, S C ^a   Bredemold, O W ^b   Kuijper, E J ^a   Mooi Kokenberg, E A N M ^c   Debast, S B ^d   Van Dissel, J T ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

^c GROENE HART HOSPITAL   (Netherlands)

^d MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL VACCINE; CLOSTRIDIUM TOXIN; NATURAL PRODUCT; UNCLASSIFIED DRUG; WHEY CONCENTRATE;

ABSENCE OF SIDE EFFECTS; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; BLOOD ANALYSIS; CLOSTRIDIUM DIFFICILE; CONFIDENCE INTERVAL; CONTROLLED STUDY; COW; DRUG SAFETY; FECES ANALYSIS; HUMAN; IMMUNIZATION; INFECTION PREVENTION; INFECTIOUS DIARRHEA; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; RECURRENT INFECTION; WHEY;

AGED; AGED, 80 AND OVER; ANIMALS; CATTLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; CONSUMER PRODUCT SAFETY; DIARRHEA; FEMALE; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; MALE; MIDDLE AGED; MILK PROTEINS; PROSPECTIVE STUDIES;

EID: 51849116486     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kuijper EJ, Dissel JT van, Wilcox MH. Clostridium difficile: changing epidemiology and new treatment options. Curr Opin Infect Dis. 2007; 20:376-83.
2. Wilcox MH, Spencer RC. Clostridium difficile infection: responses, relapses and re-infections. J Hosp Infect. 1992;22:85-92.
3. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769-75.
4. Bricker E, Garg R, Nelson R, Loza A, Novak T, Hansen J. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults [Cochrane review]. Cochrane Database Syst Rev. 2005;(1):CD004610.
5. McDonald L, Killgore GE, Thompson A, Owens jr RC, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433-41.
6. Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591-7.
7. Krausz S, Bessems M, Boermeester MA, Kuijper EJ, Visser CE, Speelman P. Levensbedreigende infecties met een nieuwe variant van Clostridium difficile. Ned Tijdschr Geneeskd. 2005;149:2081-6.
8. McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol. 2005;54:101-11.
9. Louie TJ. Treatment of first recurrences of Clostridium difficile-associated disease: waiting for new treatment options. Clin Infect Dis. 2006;42:765-7.
10. Dissel JT van, Groot N de, Hensgens CMH, Numan S, Kuijper EJ, Veldkamp P, et al. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol. 2005;4: 197-205.
11. Young KWH, Munro IC, Taylor SL, Veldkamp PJ, Dissel JT van. The safety of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile. Regul Toxicol Pharmacol. 2007;47:317-26.
12. Delmée M. Laboratory diagnosis of Clostridium difficile disease. Clin Microbiol Infect. 2001;7:411-6.
13. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13: 818-29.
14. Kemmler G, Holzner B, Kopp M, Dünser M, Margreiter R, Greil R, et al. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol. 1999;17:2932-40.
15. Steenbergen J van, Debast S, Kregten E van, Berg R van den, Notermans D, Kuijper E. Isolation of Clostridium difficile ribotype 027, toxinotype III in the Netherlands after increase in C. difficile associated diarrhoea. Euro Surveill. 2005;10:E050714.1.
16. Ruiz JLP. Antibodies from milk for the prevention and treatment of diarrheal disease. In: Indigenous antimicrobial agents of milk: recent developments. Proceedings of the IDF Seminar, August 31-September 1, 1993, Uppsala, Sweden. International Dairy Federation (IDF). Issue 2. Brussel: IDF; 1994. p. 108-21.
17. Rump JA, Arndt R, Arnold A, Bendick C, Dichtelmüller H, Franke M, et al. Treatment of diarrhoea in human immunodeficiency virus-infected patients with immunoglobulins from bovine colostrum. Clin Investig. 1992;70:588-94.
18. Tacket CO, Losonsky G, Link H, Hoang Y, Guesry P, Hilpert H, et al. Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med. 1988;318:1240-3.
19. Tacket CO, Binion SB, Bostwick E, Losonsky G, Roy MJ, Edelman R. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am J Trop Med Hyg. 1988; 47:276-83.
20. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31:1012-7.
21. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271:1913-8.
22. Wullt M, Hagslätt ML, Odenholt I. Lactobacillus plantarum 299V for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis. 2003;35: 365-7.
23. Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol. 2005;54:905-6.
24. Gorbach SL, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet. 1987; 2(8574):1519.
25. Biller JA, Katz AJ, Flores AF, Buie M, Gorbach SL. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr. 1995;21:224-6.
26. Bowden jr TA, Mansberger jr AR, Lykins LE. Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis. Am Surg. 1981;47:178-83.
27. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989;1(8648): 1156-60.
28. Lund-Tennesen S, Berstad A, Schreiner A, Midtvedt T. Clostridium difficile-associated diarrhea treated with homologous feces. Tidsskr Nor Laegeforen. 1998;118:1027-30.
29. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36:580-5.
30. Jorup-Rönström C, Håkanson A, Persson AK, Midvedt T, Norin E. Feces culture successful therapy in Clostridium difficile diarrhea. Lakartidningen. 2006;103:3603-5.
31. Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr. 1991;118:633-7.
32. Beales IL. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut. 2002;51:456.
33. Numan SC, Veldkamp P, Kuijper EJ, Berg RJ van den, Dissel JT van. Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut. 2007;56:888-9.